Chemical drug class 1 innovative drug ICP-192 obtained clinical trial approval

On July 18, 2018, InnoCare’s ICP-192 was approved for clinical trials by the State Drug Administration. ICP-192, a new class of innovative medicine developed by InnoCare subsidiary Tiancheng Pharmaceuticals, marks the third drug candidate approved for clinical trials in one year.

Gastric cancer is the second most common malignant tumor in China, with most patients being diagnosed at the advanced stages. New therapeutic options are needed for advanced-stage patients and those who have become intolerant to standard of care treatments. ICP-192 has an innovative design based on structure-activity optimization. It has shown good safety profile and efficacy in multiple solid tumor animal models.

Dr. Jisong Cui, CEO of InnoCare, said: “InnoCare sticks to its mission and strives to provide patients with better therapeutic options. China’s national policies have greatly encouraged innovation. Our R&D team will seize this opportunity to continuously introduce more and better innovative drugs for the benefit of the world.”